Neutralising antibodies and the Omicron variant: unravelling the mystery
The fourth seroprevalence study of anti-SARS-CoV-2 antibodies carried out in the Geneva population showed that eight out of ten people had defences against the Alpha and Delta variants, but that less than one in two (46.7%) had defences against the BA.4/BA.5 Omicron sub-variants. Professor Idris Guessous, head of the Swiss Primary Care Medicine Service (SMPR) and head of the study, was interviewed on Radio Télévision Suisse's 19h30 programme to comment on these new results concerning neutralising antibodies.
